Figure 5.
(A) Experimental design of the xenograft model used for assessing erufosine’s activity in vivo. Control and erufosine treated mice received twice weekly intraperitoneal injections of PBS or erufosine. (B) Change in the tumor area (mm2) between the control and erufosine treated groups during the course of experiment. A significant difference in favor of erufosine was observed in the tumor growth area between control and erufosine treated mice. (C) Mean tumor volume (mm3) of the control and erufosine treated groups at the end of the experiment. A significant reduction was seen in the tumor volume after erufosine treatment from 12 control and treated mice tumors. Asterisks denote significant differences (P < 0.05) between the control and treated cells. (D) Protein expression from excised control and treated lesions post erufosine treatment. A decrease in cyclin D1, CDK4 and CDK6 was observed in the excised treated samples when compared to the control lesions. (E) IHC (for Cyclin D1) and H&E stainings of erufosine treated and untreated tumor samples derived from the xenograft model. A reduced level of Cyclin D1 staining intensity is seen in the erufosine treated samples when compared to the untreated control groups.